Immune Checkpoint Therapy With Nivolumab Esophageal Squamous Cell Carcinoma

Condition:   Esophageal Squamous Cell Carcinoma
Intervention:   Drug: Nivolimumab+Carboplatin/paclitaxel+Radiation
Sponsor:   New York University School of Medicine
Recruiting - verified September 2017

http://ift.tt/2fdxZn6